RIO DE JANEIRO, BRAZIL - U.S. laboratory Moderna announced Thursday, June 10, that it has applied to US regulators for emergency use authorization of its vaccine against Covid-19 in adolescents between 12 and 18 years of age.
The biotech firm also requested authorization this week from the European Union and Canada and has announced its intention to do so in other countries, assuring "high effectiveness in preventing Covid-19 and SARS-CoV-2 infection" in this age group.
"We are encouraged that Moderna's vaccine was highly effective in preventing Covid-19 and SARS-CoV-2 infections in . . .